(NewsDirect)
Scancell Holdings PLC (AIM:SCLP,OTC:SCNLF) chief executive Professor Lindy Durrant speaks to ThomasWarner from Proactive to provide an update on the initial phase of theclinical stage biopharmaceutical company's Phase 2 SCOPE trial inadvanced melanoma.
Professor Durrantgives an overview of the findings so far, saying that in the initial11 patients they have achieved an impressive 82% overall responserate, surpassing the anticipated 70%. This development could becrucial for metastatic melanoma patients, as previous studies reportedonly a 50% response rate.
She adds that the potential tosignificantly improve outcomes is especially significant given therising cases, particularly among young women. While furtherconfirmation is needed in a larger cohort, the data's strengthsuggests promising results in the broader study. Looking ahead, thetrial aims to recruit 43 patients, expecting over 27 respondents, withpotential adjustments based on the remarkable initial response rate.Professor Durrant also provides an update on Modi1 vaccine andScancell's antibody platform.
ContactDetails
Proactive UK Ltd
+44 20 7989 0813
Copyright (c) 2023 TheNewswire - All rights reserved.